Navigation Links
Odyssey Thera Announces Collaboration With Mitsubishi Tanabe Pharma Corporation, and Issuance of Core Patent in Japan
Date:5/15/2009

SAN RAMON, Calif., May 15 /PRNewswire/ -- Odyssey Thera, Inc. announced today the initiation of a collaboration with leading Japanese pharmaceutical company Mitsubishi Tanabe Pharma Corporation. The alliance involves the analysis of drug candidates from a number of Mitsubishi Tanabe preclinical programs. Odyssey also announced the issuance of Japanese patent number JP 4262778, entitled "Protein fragment complementation assays for the detection of biological or drug interactions."

"We look forward to applying our patented human cell analysis technologies and proprietary drug profiling strategies to enhance Mitsubishi Tanabe's promising drug discovery programs," said Dr. John Westwick, President and CEO of Odyssey Thera. "Our partnership with Mitsubishi Tanabe, and the issuance of our Japanese patent, reflect our objective of making our unique knowledge base and enabling technologies available to quality partners around the globe."

Odyssey Thera will apply its patented Protein-fragment Complementation Assay (PCA), proprietary High Context Screening infrastructure, unique institutional knowledge, and state-of-the-art data analysis strategies in the collaboration to yield valuable insights related to drug selectivity, safety, and mechanisms of action. Financial terms of the collaboration were not disclosed.

About Odyssey Thera

Odyssey Thera, Inc. is a drug discovery company committed to identifying novel drug candidates for oncology and other chronic diseases. Odyssey Thera's live cell, pathway-based approach centers on its proprietary Protein-fragment Complementation Assay (PCA) technology and unique High Context Screening platform. Using these capabilities, Odyssey scientists have gained unique knowledge regarding cellular pathways and drug mechanisms. Odyssey's highly experienced team is using these capabilities to mine cellular systems and discover novel drug candidates for internal programs, and in partnerships with top pharmaceutical companies. To learn more about Odyssey Thera, please visit www.odysseythera.com.


'/>"/>
SOURCE Odyssey Thera, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Odyssey Thera Granted U.S. Patent for Novel GPCR Assay Strategy
2. Technical Note: E-PAGE(TM) 48- and 96-Well Gels on the Odyssey(R) Infrared Imaging System
3. LI-COR Introduces the Odyssey(R) Two-Color NIR Fluorescent Protein Molecular Weight Marker
4. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
5. Stereotaxis Highlights a Transatlantic Arrhythmia Procedure Collaboration With the Odyssey(TM) Network
6. Odyssey Thera Granted U.S. Patent for Animal Imaging
7. Cell Therapeutics Closes Italian Facility, Reduces Headcount and Expects to Cut $14 Million in Operating Expenses
8. Cell Therapeutics, Inc. (CTI) to Present at 2009 BIO International Convention
9. Orexigen(R) Therapeutics to Present at Upcoming Meetings
10. Prospect Therapeutics, Inc. Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors
11. Cell Therapeutics to Exchange up to $89.2 million of Its Outstanding Convertible Notes in a Modified Dutch Auction Tender Offer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Island, NY (PRWEB) , ... February 24, 2017 , ... ... rate. Founded in late 2014, FireflySci had the goal of bringing their powerful ... that goal continues to shape the path that FireflySci is going on as they ...
(Date:2/23/2017)... NEW YORK , Feb. 23, 2017 /PRNewswire/ ... leading digital health company, and Digital Noema ... and remote patient monitoring, announce they are partnering ... DN Telehealth maximizes collaboration compatibility for ... consultations beyond a physical clinical setting to include ...
(Date:2/23/2017)... 2017  MIODx announced today that it has ... technologies from the University of California, San Francisco ... monitor a patient for response to immune checkpoint ... second license extends the technology with a method ... have an immune-related adverse event (IRAE) from their ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... novo clearance to begin marketing the SPEAC® System, the Brain Sentinel® Seizure Monitoring ... home or in healthcare facilities during periods of rest. A lightweight, non-invasive monitor ...
Breaking Biology Technology:
(Date:2/7/2017)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, is pleased to announce that the latest release ... flexible and award winning eClinical solution, is now available ... is a proven Software-as-a-Service (SaaS) clinical research technology platform ... also delivers an entire suite of eClinical tools to ...
(Date:2/7/2017)... LONG BEACH, New York , February 7, 2017 ... formerly known as ID Global Solutions Corporation [OTC: IDGS], ... identification, identity management and electronic transaction processing services, is ... a reorganization of the Company. Effective January ... Chairman of the Board of Directors, CEO and President. ...
(Date:2/3/2017)... , Feb. 3, 2017  Texas Biomedical Research Institute ... Larry Schlesinger as the Institute,s new President ... Biomed effective May 31, 2017. He is currently the Chair ... of the Center for Microbial Interface Biology at Ohio State ... as the new President and CEO of Texas Biomed," said ...
Breaking Biology News(10 mins):